Teva Pharmaceutical Industries Net Income 2006-2018 | TEVA

Teva Pharmaceutical Industries annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Teva Pharmaceutical Industries net income for the quarter ending September 30, 2018 was $-0.273B, a 151.51% decline year-over-year.
  • Teva Pharmaceutical Industries net income for the twelve months ending September 30, 2018 was $-11.059B, a 85.46% increase year-over-year.
  • Teva Pharmaceutical Industries annual net income for 2017 was $-16.525B, a 24401.47% decline from 2016.
  • Teva Pharmaceutical Industries annual net income for 2016 was $0.068B, a 95.68% decline from 2015.
  • Teva Pharmaceutical Industries annual net income for 2015 was $1.573B, a 48.51% decline from 2014.
Teva Pharmaceutical Industries Annual Net Income
(Millions of US $)
2017 $-16,525
2016 $68
2015 $1,573
2014 $3,055
2013 $1,269
2012 $1,963
2011 $2,759
2010 $3,331
2009 $2,000
2008 $635
2007 $1,952
2006 $546
2005 $1,072
Teva Pharmaceutical Industries Quarterly Net Income
(Millions of US $)
Q3 2018 $-273
Q2 2018 $-241
Q1 2018 $1,055
Q4 2017 $-11,600
Q3 2017 $530
Q2 2017 $-6,035
Q1 2017 $580
Q4 2016 $-1,038
Q3 2016 $348
Q2 2016 $188
Q1 2016 $570
Q4 2015 $485
Q3 2015 $103
Q2 2015 $539
Q1 2015 $446
Q4 2014 $687
Q3 2014 $876
Q2 2014 $748
Q1 2014 $744
Q4 2013 $380
Q3 2013 $711
Q2 2013 $-452
Q1 2013 $630
Q4 2012 $320
Q3 2012 $-79
Q2 2012 $863
Q1 2012 $859
Q4 2011 $506
Q3 2011 $916
Q2 2011 $576
Q1 2011 $761
Q4 2010 $771
Q3 2010 $1,050
Q2 2010 $797
Q1 2010 $713
Q4 2009 $379
Q3 2009 $649
Q2 2009 $521
Q1 2009 $451
Q4 2008 $-688
Q3 2008 $637
Q2 2008 $539
Q1 2008 $147
Q4 2007 $570
Q3 2007 $525
Q2 2007 $515
Q1 2007 $342
Q4 2006 $460
Q3 2006 $606
Q2 2006 $488
Q1 2006 $-1,009
Q4 2005 $305
Q3 2005 $267
Q2 2005 $241
Q1 2005 $259
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $23.053B $22.385B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.197B 9.13
Mylan (MYL) United Kingdom $17.650B 7.27
Bausch Health Cos (BHC) Canada $9.251B 6.70
Dr Reddy's Laboratories (RDY) India $5.675B 22.66
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.575B 4.29
Supernus Pharmaceuticals (SUPN) United States $2.250B 21.32
Amphastar Pharmaceuticals (AMPH) United States $0.928B 100.65
Akorn (AKRX) United States $0.846B 0.00
Homology Medicines (FIXX) United States $0.747B 0.00
Assembly Biosciences (ASMB) United States $0.569B 0.00
CymaBay Therapeutics (CBAY) United States $0.542B 0.00
Corium (CORI) United States $0.458B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.429B 0.00
Voyager Therapeutics (VYGR) United States $0.366B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.297B 0.00
Teligent (TLGT) United States $0.153B 0.00
Sol-Gel Technologies (SLGL) Israel $0.129B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.091B 0.00
Aevi Genomic Medicine (GNMX) United States $0.073B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.051B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.030B 0.00
China Pharma Holdings (CPHI) China $0.016B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00